Literature DB >> 23671249

Pearls and pitfalls: neurostimulation in headache.

Tim P Jürgens1, Massimo Leone.   

Abstract

CONTEXT: A variety of neuromodulatory approaches available today has broadened our therapeutic options significantly especially in drug refractory patients with chronic cluster headache and chronic migraine. OVERVIEW: It is a dynamic field with a current trend to non-invasive transcutaneous stimulation approaches. However, sound studies providing evidence for the widespread use of these novel approaches are sparse. For invasive approaches, occipital nerve stimulation is now widely considered the treatment of first choice in chronic trigeminal autonomic cephalgias and - with limitations - chronic migraine. Although equally effective, deep brain stimulation is considered second-line treatment in cluster headache because of its potentially life-threatening side effects. Most recently, stimulation of the sphenopalatine ganglion has also been shown to effectively abort acute cluster headache attacks. Interesting other upcoming approaches include transcutaneous supraorbital nerve stimulation and transcutaneous vagal nerve stimulation.
CONCLUSION: Pearls and pitfalls of common invasive and non-invasive neuromodulatory approaches and open questions are summarised in this review along with recommendations for future studies.

Entities:  

Keywords:  Migraine; cluster headache; deep brain stimulation; nerve stimulation; neuromodulation

Mesh:

Year:  2013        PMID: 23671249     DOI: 10.1177/0333102413483933

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  18 in total

1.  Improved surgical procedure using intraoperative navigation for the implantation of the SPG microstimulator in patients with chronic cluster headache.

Authors:  Carsten Kohlmeier; Peter Behrens; Andreas Böger; Brinda Ramachandran; Anthony Caparso; Dirk Schulze; Philipp Stude; Max Heiland; Alexandre T Assaf
Journal:  Int J Comput Assist Radiol Surg       Date:  2017-01-12       Impact factor: 2.924

Review 2.  Supratrochlear and Supraorbital Nerve Stimulation for Chronic Headache: a Review.

Authors:  Stephanie Wrobel Goldberg; Stephanie J Nahas
Journal:  Curr Pain Headache Rep       Date:  2015-07

Review 3.  Central and Peripheral Neural Targets for Neurostimulation of Chronic Headaches.

Authors:  Massimo Leone; Alberto Proietti Cecchini
Journal:  Curr Pain Headache Rep       Date:  2017-03

4.  Non-invasive vagus nerve stimulation (nVNS) as symptomatic treatment of migraine in young patients: a preliminary safety study.

Authors:  Licia Grazzi; Gabriella Egeo; Eric Liebler; Anna Maria Padovan; Piero Barbanti
Journal:  Neurol Sci       Date:  2017-05       Impact factor: 3.307

5.  Transcutaneous supraorbital neurostimulation for the prevention of chronic migraine: a prospective, open-label preliminary trial.

Authors:  Paola Di Fiore; Gennaro Bussone; Alberto Galli; Henri Didier; Cesare Peccarisi; Domenico D'Amico; Fabio Frediani
Journal:  Neurol Sci       Date:  2017-05       Impact factor: 3.307

6.  Advanced technologies and novel neurostimulation targets in trigeminal autonomic cephalalgias.

Authors:  Giorgio Lambru; Emmanouil Giakoumakis; Adnan Al-Kaisy
Journal:  Neurol Sci       Date:  2015-05       Impact factor: 3.307

7.  Inhibitory effect of high-frequency greater occipital nerve electrical stimulation on trigeminovascular nociceptive processing in rats.

Authors:  Olga A Lyubashina; Sergey S Panteleev; Alexey Y Sokolov
Journal:  J Neural Transm (Vienna)       Date:  2016-09-27       Impact factor: 3.575

Review 8.  Update of Inpatient Treatment for Refractory Chronic Daily Headache.

Authors:  Tzu-Hsien Lai; Shuu-Jiun Wang
Journal:  Curr Pain Headache Rep       Date:  2016-01

Review 9.  Role of sphenopalatine ganglion stimulation in cluster headache.

Authors:  Tim P Jürgens; Arne May
Journal:  Curr Pain Headache Rep       Date:  2014-07

10.  Sleep-related headache and its management.

Authors:  Niranjan N Singh; Pradeep Sahota
Journal:  Curr Treat Options Neurol       Date:  2013-12       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.